<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02795403</url>
  </required_header>
  <id_info>
    <org_study_id>2009-596</org_study_id>
    <nct_id>NCT02795403</nct_id>
  </id_info>
  <brief_title>HCV Virions Bound Proteins</brief_title>
  <official_title>Hepatitis C Virus Particles-bound Human Proteins : Identification in Clinical Samples and Implication in the Viral Life Cycle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The emergence of hepatocellular carcinoma (HCC) has prompted a search for a thorough&#xD;
      understanding of the biology of one of its major causative agents, the hepatitis C virus&#xD;
      (HCV). HCV particles acquire via budding and encapsidation cellular proteins. There is&#xD;
      mounting evidence on several viral species that virion-bound proteins are prone to be&#xD;
      involved either at the replication, budding/egress or entry/release steps of the viral cycle.&#xD;
&#xD;
      Identifying such targets may yield ideal candidates for gaining insight on the dependence of&#xD;
      HCV upon a restricted subset of host proteins, therefore providing refined sets of&#xD;
      genetically stable targets for therapy. This project's goals are to set up adequate&#xD;
      conditions for robust and reproducible purification of HCV virions in clinical samples,&#xD;
      followed by the identification of their HCV-bound host proteins and the characterization of&#xD;
      their functions. Proteomics profiling of HCV particles purified from clinical samples will be&#xD;
      overlaid with proteins identified and characterized in cell culture grown HCV particles&#xD;
      during my post-doctoral training, using clinical biomarker discovery grade criteria. Targets&#xD;
      identified in both samples sets will be subjected to in vitro investigations using&#xD;
      HCV-replicating cells. Conventional biochemical and imaging methods will be used in order to:&#xD;
      (i) ascertain their physical association with HCV virions; (ii) define the modalities of&#xD;
      their interaction with HCV proteins; (iii) decipher the topology and subcellular localization&#xD;
      of their association with HCV proteins and virions; (iv) quantitatively assess their&#xD;
      functional involvement in particle budding, egress or secretion and infectivity. A candidate&#xD;
      that yielded satisfactory results in these experiments will be disclosed and further&#xD;
      investigated at the level of structural biology, in collaborative research programs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative identification (unit used: Protein Prophet score) of a given virion-bound protein in purified virions preparations</measure>
    <time_frame>One to two years after mass spectrometry identification of the candidate</time_frame>
    <description>Protein prophet scores allow one to estimate the robustness of identification of a given protein in MS approaches.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative evaluation of its implication in viral morphogenesis (unit used: TCID50).</measure>
    <time_frame>One to two years after mass spectrometry identification of the candidate</time_frame>
    <description>TCID50 units are infectivity units routinely used in HCV research for viral infectivity quantification.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantitative evaluation of viral entry (unit used: HCV RNA /GUS mRNA copy ratios).</measure>
    <time_frame>One to two years after mass spectrometry identification of the candidate</time_frame>
    <description>HCV RNA /GUS mRNA copy ratios are derived from the 2^delta(delta Ct) method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical virions datasets with in vitro grown virions datasets</measure>
    <time_frame>One to two years after mass spectrometry identification of the candidate</time_frame>
    <description>Proteins identified from viral particles purified from clinical samples will be compared to proteins identified in viral particles from cells of human hepatocarcinoma (Huh7.5) infected with HCV and from which data are published.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Viraemic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>responder group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood draw of 150ml, twice</intervention_name>
    <arm_group_label>Viraemic</arm_group_label>
    <arm_group_label>responder group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult&gt; 18 and &lt;60 years&#xD;
&#xD;
          -  Infected with HCV genotype 1 HCV antibody positive.&#xD;
&#xD;
          -  positive viremia for more than 6 months&#xD;
&#xD;
          -  Viremia&gt; 106 IU / ml.&#xD;
&#xD;
          -  nonresponders to previous treatment and without antiviral treatment for 2 months.&#xD;
&#xD;
          -  For control samples: Patients responders to previous treatment and without antiviral&#xD;
             treatment for 2 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient receiving or having received antiviral treatment within two months.&#xD;
&#xD;
          -  patient with against-indication for a blood sample of 150 ml&#xD;
&#xD;
          -  immunosuppressive therapy patient&#xD;
&#xD;
          -  Patient with liver disease other than hepatitis C.&#xD;
&#xD;
          -  Patients with cirrhosis.&#xD;
&#xD;
          -  patient with hepatocellular carcinoma.&#xD;
&#xD;
          -  Patients with one or more severe co-morbidities defined as:&#xD;
&#xD;
          -  Co-infection with HIV or HBV.&#xD;
&#xD;
          -  hematological malignancies changing or aplasia&#xD;
&#xD;
          -  Insulin-dependent diabetes&#xD;
&#xD;
          -  dialyzed chronic renal failure&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Persons subject to legal protection or the subject of a safeguard measure of justice&#xD;
             not affiliated with a social security scheme or not beneficiaries of such a scheme&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien ZOULIM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service d'Hépato-Gastroentérologie Lyon Croix-Rousse Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hépato-Gastroentérologie Lyon Croix-Rousse Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>June 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2016</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV, liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

